Scilex Holding Company (SCLX) NASDAQ
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Scilex Holding Company
Address
960 San Antonio Road
Palo Alto, CA 94303
United States of America (the)
Phone
650-516-4310
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
34
First IPO Date
March 05, 2021
Key Executives
| Name | Title | Pay | Year Born |
| Henry H. Ji | Chief Executive Officer, President & Executive Chairman | 1.58M | 1964 |
| Suresh K. Khemani | Senior Vice President, Chief Commercial Officer & GM of Scilex Pharma | 456,820 | 1960 |
| Dmitri V. Lissin | Senior Vice President of Clinical Development and Medical Affairs & Interim Chief Medical Officer | 528,826 | 1959 |
| Stephen Ma | Senior Vice President, Chief Financial Officer, Chief Operating Officer, Corporate Secretary & Director | 718,783 | 1973 |
| Suketu D. Desai | Interim Chief Technical Officer & Senior Vice President | 0 | 1965 |
| Gigi DeGuzman | Vice President & Chief People Officer | 0 | N/A |
Description
Scilex Holding Company is a biopharmaceutical enterprise that specializes in the development and market introduction of non-opioid therapies designed to alleviate both acute and chronic pain. Its primary marketed offering is ZTlido 1.8%, a topical prescription formulation of lidocaine specifically engineered to mitigate neuropathic discomfort associated with post-herpetic neuralgia, a condition characterized by persistent nerve pain following shingles. Beyond this, the company's development pipeline includes SP-102, a viscous gel corticosteroid for epidural administration, currently undergoing Phase III trials for lumbosacral radicular pain. Another candidate, SP-103, is progressing through Phase II trials for managing low back pain. Furthermore, SP-104, a novel, low-dose, delayed-release naltrexone hydrochloride formulation, has successfully concluded Phase I clinical testing for the treatment of fibromyalgia. Its corporate offices are situated in Palo Alto, California. Scilex Holding Company operates as a subsidiary of Sorrento Therapeutics, Inc.
